GlassScriptPhysician profile
Ashraf Mahmood
NPI 1457988495
$462.53
in general payments reported to CMS, 2019-2025
10 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $46.52 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $103.12 | 2025 | Zepbound, Mounjaro, Kisunla |
| Axsome Therapeutics, INC. | $76.96 | 2025 | Auvelity |
| Ardelyx, INC. | $73.74 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $46.74 | 2024-2025 | Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $44.89 | 2025 | Nuzyra, Xhance |
| Hologic Sales and Service, LLC | $32.38 | 2024 | Aptima |
| Novo Nordisk INC | $28.34 | 2025 | Wegovy |
| Mayne Pharma Commercial LLC | $21.26 | 2025 | |
| Alk-Abello, INC | $20.83 | 2025 | Grastek, Odactra, Ragwitek |
| Intra-Sana Laboratories | $14.27 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.